Diffuse large B-cell lymphoma (DLBCL) is usually treated by chemotherapy together with an antibody therapy called rituximab. However, this approach is not always successful - many people do not respond, or only have a partial response, so further 'salvage' treatment is needed. If salvage treatment is unsucessful, a stem cell transplant may be given, but sometimes the DLBCL returns after this.
We are looking for new ways to treat people with DLBCL who have not responded to the standard treatment of chemotherapy and antibody therapy.
The TORCH trial is looking at a new drug called vistusertib for people with DLBCL that has continued to grow during standard treatment, or has come back afterwards.
We are also supporting the COBALT trial, which is using a CAR-T therapy in people who have DLBCL that has returned after a stem cell transplant. CAR-T therapy involves researchers genetically modifiying donor immune cells (T-cells) to seek out the DLBCL cancer cells in patients, and it's the first time this type of treatment has been used for people with DLBCL.